Explore › Condition › Non-alcoholic Fatty Liver Disease
Condition

Non-alcoholic Fatty Liver Disease

Also known as: Fatty Liver, Nonalcoholic Fatty Livers, Nonalcoholic Liver, Nonalcoholic Fatty Livers, Nonalcoholic Fatty MASLD - metabolic dysfunction-associated steatotic liver disease Metabolic dysfunction-associated steatotic liver disease Metabolic dysfunction-associated steatotic liver disease (disorder) NAFL - non-alcoholic fatty liver NAFLD NAFLD - Nonalcoholic fatty liver disease NAFLD - nonalcoholic fatty liver disease Non alcoholic Fatty Liver Disease +12 more
3 findings 1 paper 4 related entities View in graph →

Related entities

interventions
Hypoglycemic Sulfonylureas1
outcomes
Hepatocellular carcinoma1
populations
Type 2 Diabetes Patients1
studys
PMC91075291

Findings (27)

None
null

In patients with NAFLD and diabetes, sulfonylureas alone and in combination with other oral diabetes medications did not significantly reduce the risk of hepatocellular carcinoma.

Effect: null; HR 0.89; CI: 95% CI 0.73-1.08

Size: HR 0.89 CI: 95% CI 0.73-1.08
PMC9107529
Finding details → · Paper → · Graph →
None
null

In patients with NAFLD and diabetes, sulfonylureas alone and in combination with other oral diabetes medications did not significantly reduce the risk of hepatocellular carcinoma.

Effect: null; HR 0.89; CI: 95% CI 0.73-1.08

Size: HR 0.89 CI: 95% CI 0.73-1.08
PMC9107529
Finding details → · Paper → · Graph →
None
null

In patients with NAFLD and diabetes, sulfonylureas alone and in combination with other oral diabetes medications did not significantly reduce the risk of hepatocellular carcinoma.

Effect: null; HR 0.89; CI: 95% CI 0.73-1.08

Size: HR 0.89 CI: 95% CI 0.73-1.08
PMC9107529
Finding details → · Paper → · Graph →
None
null

In patients with NAFLD and diabetes, sulfonylureas alone and in combination with other oral diabetes medications did not significantly reduce the risk of hepatocellular carcinoma.

Effect: null; HR 0.89; CI: 95% CI 0.73-1.08

Size: HR 0.89 CI: 95% CI 0.73-1.08
PMC9107529
Finding details → · Paper → · Graph →
None
null

In patients with NAFLD and diabetes, sulfonylureas alone and in combination with other oral diabetes medications did not significantly reduce the risk of hepatocellular carcinoma.

Effect: null; HR 0.89; CI: 95% CI 0.73-1.08

Size: HR 0.89 CI: 95% CI 0.73-1.08
PMC9107529
Finding details → · Paper → · Graph →
None
null

In patients with NAFLD and diabetes, sulfonylureas alone and in combination with other oral diabetes medications did not significantly reduce the risk of hepatocellular carcinoma.

Effect: null; HR 0.89; CI: 95% CI 0.73-1.08

Size: HR 0.89 CI: 95% CI 0.73-1.08
PMC9107529
Finding details → · Paper → · Graph →
None
null

In patients with NAFLD and diabetes, sulfonylureas alone and in combination with other oral diabetes medications did not significantly reduce the risk of hepatocellular carcinoma.

Effect: null; HR 0.89; CI: 95% CI 0.73-1.08

Size: HR 0.89 CI: 95% CI 0.73-1.08
PMC9107529
Finding details → · Paper → · Graph →
None
null

In patients with NAFLD and diabetes, sulfonylureas alone and in combination with other oral diabetes medications did not significantly reduce the risk of hepatocellular carcinoma.

Effect: null; HR 0.89; CI: 95% CI 0.73-1.08

Size: HR 0.89 CI: 95% CI 0.73-1.08
PMC9107529
Finding details → · Paper → · Graph →
None
null

In patients with NAFLD and diabetes, sulfonylureas alone and in combination with other oral diabetes medications did not significantly reduce the risk of hepatocellular carcinoma.

Effect: null; HR 0.89; CI: 95% CI 0.73-1.08

Size: HR 0.89 CI: 95% CI 0.73-1.08
PMC9107529
Finding details → · Paper → · Graph →
None
null

In patients with NAFLD and diabetes, sulfonylureas alone and in combination with other oral diabetes medications did not significantly reduce the risk of hepatocellular carcinoma.

Effect: null; HR 0.89; CI: 95% CI 0.73-1.08

Size: HR 0.89 CI: 95% CI 0.73-1.08
PMC9107529
Finding details → · Paper → · Graph →
None
null

In patients with NAFLD and diabetes, sulfonylureas alone and in combination with other oral diabetes medications did not significantly reduce the risk of hepatocellular carcinoma.

Effect: null; HR 0.89; CI: 95% CI 0.73-1.08

Size: HR 0.89 CI: 95% CI 0.73-1.08
PMC9107529
Finding details → · Paper → · Graph →
None
null

In patients with NAFLD and diabetes, sulfonylureas alone and in combination with other oral diabetes medications did not significantly reduce the risk of hepatocellular carcinoma.

Effect: null; HR 0.89; CI: 95% CI 0.73-1.08

Size: HR 0.89 CI: 95% CI 0.73-1.08
PMC9107529
Finding details → · Paper → · Graph →
None
null

In patients with NAFLD and diabetes, sulfonylureas alone and in combination with other oral diabetes medications did not significantly reduce the risk of hepatocellular carcinoma.

Effect: null; HR 0.89; CI: 95% CI 0.73-1.08

Size: HR 0.89 CI: 95% CI 0.73-1.08
PMC9107529
Finding details → · Paper → · Graph →
None
null

In patients with NAFLD and diabetes, sulfonylureas alone and in combination with other oral diabetes medications did not significantly reduce the risk of hepatocellular carcinoma.

Effect: null; HR 0.89; CI: 95% CI 0.73-1.08

Size: HR 0.89 CI: 95% CI 0.73-1.08
PMC9107529
Finding details → · Paper → · Graph →
None
null

In patients with NAFLD and diabetes, sulfonylureas alone and in combination with other oral diabetes medications did not significantly reduce the risk of hepatocellular carcinoma.

Effect: null; HR 0.89; CI: 95% CI 0.73-1.08

Size: HR 0.89 CI: 95% CI 0.73-1.08
PMC9107529
Finding details → · Paper → · Graph →
None
null

In patients with NAFLD and diabetes, sulfonylureas alone and in combination with other oral diabetes medications did not significantly reduce the risk of hepatocellular carcinoma.

Effect: null; HR 0.89; CI: 95% CI 0.73-1.08

Size: HR 0.89 CI: 95% CI 0.73-1.08
PMC9107529
Finding details → · Paper → · Graph →
None
null

In patients with NAFLD and diabetes, sulfonylureas alone and in combination with other oral diabetes medications did not significantly reduce the risk of hepatocellular carcinoma.

Effect: null; HR 0.89; CI: 95% CI 0.73-1.08

Size: HR 0.89 CI: 95% CI 0.73-1.08
PMC9107529
Finding details → · Paper → · Graph →
None
null

In patients with NAFLD and diabetes, sulfonylureas alone and in combination with other oral diabetes medications did not significantly reduce the risk of hepatocellular carcinoma.

Effect: null; HR 0.89; CI: 95% CI 0.73-1.08

Size: HR 0.89 CI: 95% CI 0.73-1.08
PMC9107529
Finding details → · Paper → · Graph →
None
null

In patients with NAFLD and diabetes, sulfonylureas alone and in combination with other oral diabetes medications did not significantly reduce the risk of hepatocellular carcinoma.

Effect: null; HR 0.89; CI: 95% CI 0.73-1.08

Size: HR 0.89 CI: 95% CI 0.73-1.08
PMC9107529
Finding details → · Paper → · Graph →
None
null

In patients with NAFLD and diabetes, sulfonylureas alone and in combination with other oral diabetes medications did not significantly reduce the risk of hepatocellular carcinoma.

Effect: null; HR 0.89; CI: 95% CI 0.73-1.08

Size: HR 0.89 CI: 95% CI 0.73-1.08
PMC9107529
Finding details → · Paper → · Graph →
None
null

In patients with NAFLD and diabetes, sulfonylureas alone and in combination with other oral diabetes medications did not significantly reduce the risk of hepatocellular carcinoma.

Effect: null; HR 0.89; CI: 95% CI 0.73-1.08

Size: HR 0.89 CI: 95% CI 0.73-1.08
PMC9107529
Finding details → · Paper → · Graph →
None
null

In patients with NAFLD and diabetes, sulfonylureas alone and in combination with other oral diabetes medications did not significantly reduce the risk of hepatocellular carcinoma.

Effect: null; HR 0.89; CI: 95% CI 0.73-1.08

Size: HR 0.89 CI: 95% CI 0.73-1.08
PMC9107529
Finding details → · Paper → · Graph →
None
null

In patients with NAFLD and diabetes, sulfonylureas alone and in combination with other oral diabetes medications did not significantly reduce the risk of hepatocellular carcinoma.

Effect: null; HR 0.89; CI: 95% CI 0.73-1.08

Size: HR 0.89 CI: 95% CI 0.73-1.08
PMC9107529
Finding details → · Paper → · Graph →
None
null

In patients with NAFLD and diabetes, sulfonylureas alone and in combination with other oral diabetes medications did not significantly reduce the risk of hepatocellular carcinoma.

Effect: null; HR 0.89; CI: 95% CI 0.73-1.08

Size: HR 0.89 CI: 95% CI 0.73-1.08
PMC9107529
Finding details → · Paper → · Graph →
None
null

In patients with NAFLD and diabetes, sulfonylureas alone and in combination with other oral diabetes medications did not significantly reduce the risk of hepatocellular carcinoma.

Effect: null; HR 0.89; CI: 95% CI 0.73-1.08

Size: HR 0.89 CI: 95% CI 0.73-1.08
PMC9107529
Finding details → · Paper → · Graph →
None
null

In patients with NAFLD and diabetes, sulfonylureas alone and in combination with other oral diabetes medications did not significantly reduce the risk of hepatocellular carcinoma.

Effect: null; HR 0.89; CI: 95% CI 0.73-1.08

Size: HR 0.89 CI: 95% CI 0.73-1.08
PMC9107529
Finding details → · Paper → · Graph →
None
null

In patients with NAFLD and diabetes, sulfonylureas alone and in combination with other oral diabetes medications did not significantly reduce the risk of hepatocellular carcinoma.

Effect: null; HR 0.89; CI: 95% CI 0.73-1.08

Size: HR 0.89 CI: 95% CI 0.73-1.08
PMC9107529
Finding details → · Paper → · Graph →

Papers (1)